Abstract:Background Currently, there are no drugs that have been proven to be effective against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Because of its broad antiviral activity, interferon (IFN) should be evaluated as a potential therapeutic agent for treatment of coronavirus disease 2019 (COVID-19), especially while COVID-19-specific therapies are still under development. Methods Confirmed COVID-19 patients hospitalized in the First Affiliated Hospital, School of Medicine, Zhejiang University in Hangzhou, China, from January 19 to February 19, 2020 were enrolled in a retrospective study. The patients were separated into an IFN group and a control group according to whether they received initial IFN-α2b inhalation treatment after admission. Propensity-score matching was used to balance the confounding factors. Results A total of 104 confirmed COVID-19 patients, 68 in the IFN group and 36 in the control group, were enrolled. Less hypertension (27.9% vs. 55.6%, P =0.006), dyspnea (8.8% vs. 25.0%, P =0.025), or diarrhea (4.4% vs. 19.4%, P =0.030) was observed in the IFN group. Lower levels of albumin and C-reactive protein and higher level of sodium were observed in the IFN group. Glucocorticoid dosage was lower in the IFN group (median, 40 vs. 80 mg/d, P =0.025). Compared to the control group, fewer patients in the IFN group were ventilated (13.2% vs. 33.3%, P =0.015) and admitted to intensive care unit (ICU) (16.2% vs. 44.4%, P =0.002). There were also fewer critical patients in the IFN group (7.4% vs. 25.0%, P =0.017) upon admission. Although complications during admission process were comparable between groups, the discharge rate (85.3% vs. 66.7%, P =0.027) was higher and the hospitalization time (16 vs. 21 d, P =0.015) was shorter in the IFN group. When other confounding factors were not considered, virus shedding time (10 vs. 13 d, P =0.014) was also shorter in the IFN group. However, when the influence of other factors was eliminated using propensity score matching, virus shedding time was not significantly shorter than that of the control group (12 vs. 15 d, P =0.206). Conclusions IFN-α2b spray inhalation did not shorten virus shedding time of SARS-CoV-2 in hospitalized patients.

Decreased B Cells on Admission was Associated with Prolonged Virus Shedding from Respiratory Tract in Coronavirus Disease 2019: A Case Control Study

Decreased Cells on Admission was Associated with Prolonged Virus Shedding from Respiratory Tract in Coronavirus Disease 2019: A Case Control Study

Decreased B Cells On Admission Associated With Prolonged Viral Rna Shedding From The Respiratory Tract In Coronavirus Disease 2019: A Case-Control Study

Clinical Characteristics and Factors Associated with Long-Term Viral Excretion in Patients with Severe Acute Respiratory Syndrome Coronavirus 2 Infection: a Single-Center 28-Day Study

Factors Associated With Prolonged Viral RNA Shedding in Patients with Coronavirus Disease 2019 (COVID-19)

Characteristics of Viral Shedding Time in SARS-CoV-2 Infections: A Systematic Review and Meta-Analysis.

Clinical Features in Coronavirus Disease 2019 (COVID-19) Patients with Early Clearance and Prolonged Shedding of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) RNA.

Development and validation of an individualized nomogram for early prediction of the duration of SARS-CoV-2 shedding in COVID-19 patients with non-severe disease

Prevalence and Persistent Shedding of Fecal SARS-CoV-2 RNA in Patients with COVID-19 Infection: A Systematic Review and Meta-analysis.

Clinical Course and Factors Associated with Viral RNA Shedding and Radiologic Resolution in Patients with COVID-19: a Retrospective Study

Delayed Clearance of Viral RNA in Sputum for Severity COVID-19 Patients with Initial High Viral Load

Characteristics of COVID-19 Patients With SARS-CoV-2 Positivity in Feces

Immune Characteristics of Patients with Coronavirus Disease 2019 (COVID-19)

Prolonged viral RNA shedding is associated with improved prognosis in COVID-19 patients: a retrospective cohort study

Associations of Clinical Features and Dynamic Immune Response with the Duration of Viral RNA Shedding in Patients with COVID-19

Prolonged viral shedding of SARS-CoV-2 and related factors in symptomatic COVID-19 patients: a prospective study

Comorbidities prolonged viral shedding of patients infected with SARS-CoV-2 omicron variant in Shanghai: A multi-center, retrospective, observational study

Prolonged Shedding of Severe Acute Respiratory Syndrome Coronavirus 2 in Patients with COVID-19

Longitudinal Virological Changes and Underlying Pathogenesis in Hospitalized COVID-19 Patients in Guangzhou, China

Factors Associated with Prolonged Viral Shedding of SARS-CoV-2 Omicron Variant Infection in Shanghai: A Multicenter, Retrospective, Observational Study.

Interferon-α2b Spray Inhalation Did Not Shorten Virus Shedding Time of SARS-CoV-2 in Hospitalized Patients: a Preliminary Matched Case-Control Study